Catalyst Biosciences Inc
F:HGF2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Catalyst Biosciences Inc
Short-Term Debt
Catalyst Biosciences Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Catalyst Biosciences Inc
F:HGF2
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Debt
$2.5B
|
CAGR 3-Years
1 257%
|
CAGR 5-Years
136%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Catalyst Biosciences Inc
Glance View
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with the progression of the disease state. Its pipeline consists of a preclinical complement component 3 (C3) degrader program for geographic atrophy (GA) in dry age-related macular degeneration (dAMD), an improved Complement Factor I (CFI) protease, CB 4332, for subcutaneous (SQ) or intravitreal (IVT) therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. The Company’s portfolio consists of development candidates, which include CB 4332 and CB 2782-PEG.
See Also
What is Catalyst Biosciences Inc's Short-Term Debt?
Short-Term Debt
0
USD
Based on the financial report for Dec 31, 2022, Catalyst Biosciences Inc's Short-Term Debt amounts to 0 USD.
